{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:25:58Z","timestamp":1772036758637,"version":"3.50.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["112CM-TMU-08"],"award-info":[{"award-number":["112CM-TMU-08"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11523-024-01118-0","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T08:52:42Z","timestamp":1733820762000},"page":"71-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies"],"prefix":"10.1007","volume":"20","author":[{"given":"Hui-Chen","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-834X","authenticated-orcid":false,"given":"Ka-Wai","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 2016;34:3069\u2013103. https:\/\/doi.org\/10.1200\/JCO.2016.67.1487.","journal-title":"J Clin Oncol"},{"key":"1118_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111322","volume":"532","author":"F Rasha","year":"2021","unstructured":"Rasha F, Sharma M, Pruitt K. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532: 111322. https:\/\/doi.org\/10.1016\/j.mce.2021.111322.","journal-title":"Mol Cell Endocrinol"},{"key":"1118_CR4","first-page":"2315","volume":"12","author":"L Altucci","year":"1996","unstructured":"Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 1996;12:2315\u201324.","journal-title":"Oncogene"},{"key":"1118_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1:338\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0101.","journal-title":"Cancer Discov"},{"key":"1118_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Prado MD, Lallena MJ, et al. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs. 2014;32:825\u201337. https:\/\/doi.org\/10.1007\/s10637-014-0120-7.","journal-title":"Invest New Drugs"},{"key":"1118_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1389557522666220606095540","volume":"23","author":"MA Hassan","year":"2023","unstructured":"Hassan MA, Ates-Alagoz Z. Cyclin-dependent kinase 4\/6 inhibitors against breast cancer. Mini Rev Med Chem. 2023;23:412\u201328. https:\/\/doi.org\/10.2174\/1389557522666220606095540.","journal-title":"Mini Rev Med Chem"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cort\u00e9s J, Di\u00e9ras V, Patt D, et al. MONARCH 1, a phase ii study of abemaciclib, a cdk4 and cdk6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(\u2212) metastatic breast cancer. Clin Cancer Res. 2017;23:5218\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0754.","journal-title":"Clin Cancer Res"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2\u2212 advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1758835920963925. https:\/\/doi.org\/10.1177\/1758835920963925.","journal-title":"Ther Adv Med Oncol."},{"key":"1118_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21:763\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(20)30112-1.","journal-title":"Lancet Oncol"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(\u2212) breast cancer. Clin Cancer Res. 2020;26:566\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1425.","journal-title":"Clin Cancer Res"},{"key":"1118_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-022-06662-9","volume":"195","author":"E Hamilton","year":"2022","unstructured":"Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, et al. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2\u2212 metastatic breast cancer. Breast Cancer Res Treat. 2022;195:55\u201364. https:\/\/doi.org\/10.1007\/s10549-022-06662-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)71159-3.","journal-title":"Lancet Oncol"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719\u201329. https:\/\/doi.org\/10.1007\/s10549-018-05125-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0.","journal-title":"Lancet Oncol"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","volume":"175","author":"B Xu","year":"2022","unstructured":"Xu B, Hu X, Li W, Sun T, Shen K, Wang S, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 2022;175:236\u201345. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.012.","journal-title":"Eur J Cancer"},{"key":"1118_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, Laurentiis MD, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1911149.","journal-title":"N Engl J Med"},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"key":"1118_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5455\/medarh.2022.76.333-342","volume":"76","author":"D Hermansyah","year":"2022","unstructured":"Hermansyah D, Firsty NN, Alhudawy MN, Nasution RA. The combination of CDK 4\/6 inhibitors plus endocrine treatment versus endocrine treatment alone in hormone-receptor (HR)-positive breast cancer: a systematic review and meta-analysis. Med Arch. 2022;76:333\u201342. https:\/\/doi.org\/10.5455\/medarh.2022.76.333-342.","journal-title":"Med Arch."},{"key":"1118_CR23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-023-11322-2","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu J, Ji Z, Chen L, Zou J, Zheng J, et al. Comparative efficacy and safety of different combinations of three CDK4\/6 inhibitors with endocrine therapies in HR+\/HER-2\u2014metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer. 2023;23:816. https:\/\/doi.org\/10.1186\/s12885-023-11322-2.","journal-title":"BMC Cancer"},{"key":"1118_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14740338.2021.1931116","volume":"20","author":"JH Leung","year":"2021","unstructured":"Leung JH, Leung HWC, Wang SY, Huang SS, Chan ALF. Efficacy and safety of CDK4\/6 and PI3K\/AKT\/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis. Expert Opin Drug Saf. 2021;20:949\u201357. https:\/\/doi.org\/10.1080\/14740338.2021.1931116.","journal-title":"Expert Opin Drug Saf"},{"key":"1118_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","volume":"112","author":"F Schettini","year":"2020","unstructured":"Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Mastro LD, et al. Overall survival of CDK4\/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. J Natl Cancer Inst. 2020;112:1089\u201397. https:\/\/doi.org\/10.1093\/jnci\/djaa071.","journal-title":"J Natl Cancer Inst"},{"key":"1118_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s41649-019-00095-1","volume":"11","author":"W Lipworth","year":"2019","unstructured":"Lipworth W. Real-world data to generate evidence about healthcare interventions: the application of an ethics framework for big data in health and research. Asian Bioeth Rev. 2019;11:289\u201398. https:\/\/doi.org\/10.1007\/s41649-019-00095-1.","journal-title":"Asian Bioeth Rev."},{"key":"1118_CR27","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s00268-010-0683-1","volume":"34","author":"SP Leong","year":"2010","unstructured":"Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308\u201324. https:\/\/doi.org\/10.1007\/s00268-010-0683-1.","journal-title":"World J Surg"},{"key":"1118_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339: b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"BMJ"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12874-019-0780-2","volume":"19","author":"HTN Giang","year":"2019","unstructured":"Giang HTN, Ahmed AM, Fala RY, Khattab MM, Othman MHA, Abdelrahman SAM, et al. Methodological steps used by authors of systematic reviews and meta-analyses of clinical trials: a cross-sectional study. BMC Med Res Methodol. 2019;19:164. https:\/\/doi.org\/10.1186\/s12874-019-0780-2.","journal-title":"BMC Med Res Methodol"},{"key":"1118_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1118_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Jelena Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1118_CR32","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"1118_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"J Higgins","year":"2019","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: Wiley; 2019.","edition":"2"},{"key":"1118_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"1118_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v049.i05","volume":"49","author":"BC Wallace","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1\u201315. https:\/\/doi.org\/10.18637\/jss.v049.i05.","journal-title":"J Stat Softw"},{"key":"1118_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2021.11.010","volume":"161","author":"J Albanell","year":"2022","unstructured":"Albanell J, Mart\u00ednez MT, Ramos M, O\u2019Connor M, de la Cruz-Merino L, Santaballa A, et al. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive\/HER2-advanced breast cancer: GEICAM\/2014-12 (FLIPPER). Eur J Cancer. 2022;161:26\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.010.","journal-title":"Eur J Cancer"},{"key":"1118_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejca.2022.01.014","volume":"166","author":"S Delaloge","year":"2022","unstructured":"Delaloge S, Dureau S, D\u2019Hondt V, Desmoulins I, Heudel PE, Duhoux FP, et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer. 2022;166:300\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.014.","journal-title":"Eur J Cancer"},{"key":"1118_CR38","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","volume":"20","author":"YH Park","year":"2019","unstructured":"Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019;20:1750\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30565-0.","journal-title":"Lancet Oncol"},{"key":"1118_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22:212\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(20)30642-2.","journal-title":"Lancet Oncol"},{"key":"1118_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","volume":"168","author":"M Mart\u00edn","year":"2022","unstructured":"Mart\u00edn M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Mu\u00f1oz M, et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.006.","journal-title":"Eur J Cancer"},{"key":"1118_CR41","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","volume":"30","author":"KL Jhaveri","year":"2024","unstructured":"Jhaveri KL, Bellet-Ezquerra M, Turner NC, Loi S, Bardia A, Boni V, et al. Phase Ia\/b study of giredestrant \u00b1 palbociclib and \u00b1 luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer. Clin Cancer Res. 2024;30:754\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1796.","journal-title":"Clin Cancer Res"},{"key":"1118_CR42","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN Trial. J Clin Oncol. 2023;41:4004\u201313. https:\/\/doi.org\/10.1200\/JCO.22.02392.","journal-title":"J Clin Oncol"},{"key":"1118_CR43","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol. 2021;39:1518\u201330. https:\/\/doi.org\/10.1200\/JCO.20.03639.","journal-title":"J Clin Oncol"},{"key":"1118_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat A, Saura C, Pascual T, Hernando C, Mu\u00f1oz M, Par\u00e9 L, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21:33\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(19)30786-7.","journal-title":"Lancet Oncol"},{"key":"1118_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","volume":"54","author":"A Schneeweiss","year":"2020","unstructured":"Schneeweiss A, Ettl J, L\u00fcftner D, Beckmann MW, Belleville E, Fasching PA, et al. Initial experience with CDK4\/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer\u2014data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast. 2020;54:88\u201395. https:\/\/doi.org\/10.1016\/j.breast.2020.08.011.","journal-title":"Breast"},{"key":"1118_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-023-06911-5","volume":"199","author":"K Watanabe","year":"2023","unstructured":"Watanabe K, Niikura N, Kikawa Y, Oba M, Kobayashi K, Tada H, et al. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive\/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Res Treat. 2023;199:253\u201363. https:\/\/doi.org\/10.1007\/s10549-023-06911-5.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101604","volume":"14","author":"O Avc\u0131","year":"2023","unstructured":"Avc\u0131 O, \u0130ria\u011fa\u00e7 Y, \u00c7avdar E, Karaboyun K, Araz M, \u015eakalar T, et al. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: a prospective real-world TOG study. J Geriatr Oncol. 2023;14: 101604. https:\/\/doi.org\/10.1016\/j.jgo.2023.101604.","journal-title":"J Geriatr Oncol."},{"key":"1118_CR48","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10549-021-06334-0","volume":"189","author":"M De Laurentiis","year":"2021","unstructured":"De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, et al. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat. 2021;189:689\u201399. https:\/\/doi.org\/10.1007\/s10549-021-06334-0.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13058-020-01334-2","volume":"22","author":"L Cabel","year":"2020","unstructured":"Cabel L, Rosenblum D, Lerebours F, Brain E, Loirat D, Bergqvist M, et al. Plasma thymidine kinase 1 activity and outcome of ER+ HER2\u2212 metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res. 2020;22:98. https:\/\/doi.org\/10.1186\/s13058-020-01334-2.","journal-title":"Breast Cancer Res"},{"key":"1118_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/oncolo\/oyac205","volume":"28","author":"S Di Cosimo","year":"2023","unstructured":"Di Cosimo S, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil MJG, Borrego MR, et al. Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive\/HER2-negative advanced breast cancer: a detailed safety analysis of the randomized parsifal trial. Oncologist. 2023;28:23\u201332. https:\/\/doi.org\/10.1093\/oncolo\/oyac205.","journal-title":"Oncologist"},{"key":"1118_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113480","volume":"198","author":"PA Fasching","year":"2023","unstructured":"Fasching PA, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, et al. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. Eur J Cancer. 2023;198: 113480. https:\/\/doi.org\/10.1016\/j.ejca.2023.113480.","journal-title":"Eur J Cancer"},{"key":"1118_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40261-023-01294-3","volume":"43","author":"L Fein","year":"2023","unstructured":"Fein L, Lazaretti N, Chuken YL, Benfield JRGR, Mano MS, Lobaton J, et al. Expanded access study of palbociclib plus letrozole for postmenopausal women with HR+\/HER2\u2212 advanced breast cancer in latin america for whom letrozole therapy is deemed appropriate. Clin Drug Investig. 2023;43:699\u2013706. https:\/\/doi.org\/10.1007\/s40261-023-01294-3.","journal-title":"Clin Drug Investig"},{"key":"1118_CR53","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","volume":"24","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24:1029\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(23)00268-1.","journal-title":"Lancet Oncol"},{"key":"1118_CR54","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","volume":"7","author":"A Llombart-Cussac","year":"2021","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil-Gil M, Ru\u00edz-Borrego M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol. 2021;7:1791\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4301.","journal-title":"JAMA Oncol"},{"key":"1118_CR55","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/ajco.13653","volume":"18","author":"S Loi","year":"2022","unstructured":"Loi S, Karapetis CS, McCarthy N, Oakman C, Redfern A, White M, et al. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: an expanded access study in Australia and India. Asia Pac J Clin Oncol. 2022;18:560\u20139. https:\/\/doi.org\/10.1111\/ajco.13653.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1118_CR56","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/annonc\/mdy214","volume":"29","author":"L Malorni","year":"2018","unstructured":"Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D\u2019Hollander K, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 2018;29:1748\u201354. https:\/\/doi.org\/10.1093\/annonc\/mdy214.","journal-title":"Ann Oncol"},{"key":"1118_CR57","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/annonc\/mdz198","volume":"30","author":"EL Mayer","year":"2019","unstructured":"Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, et al. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019;30:1514\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdz198.","journal-title":"Ann Oncol"},{"key":"1118_CR58","doi-asserted-by":"publisher","first-page":"175883592098765","DOI":"10.1177\/1758835920987651","volume":"13","author":"R Palumbo","year":"2021","unstructured":"Palumbo R, Torrisi R, Sottotetti F, Presti D, Gambaro AR, Collov\u00e0 E, et al. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive\/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study. Ther Adv Med Oncol. 2021;13:1758835920987651. https:\/\/doi.org\/10.1177\/1758835920987651.","journal-title":"Ther Adv Med Oncol."},{"key":"1118_CR59","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3332\/ecancer.2020.1058","volume":"14","author":"F Petracci","year":"2020","unstructured":"Petracci F, Abuin GG, Pini A, Chac\u00f3n M. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use. Ecancermedicalscience. 2020;14:1058. https:\/\/doi.org\/10.3332\/ecancer.2020.1058.","journal-title":"Ecancermedicalscience."},{"key":"1118_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114906","volume":"164","author":"R Roncato","year":"2023","unstructured":"Roncato R, Peruzzi E, Gerratana L, Posocco B, Nuzzo S, Montico M, et al. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure. Biomed Pharmacother. 2023;164: 114906. https:\/\/doi.org\/10.1016\/j.biopha.2023.114906.","journal-title":"Biomed Pharmacother"},{"key":"1118_CR61","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26:5310\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1764.","journal-title":"Clin Cancer Res"},{"key":"1118_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-023-01678-5","volume":"25","author":"F Alves da Costa","year":"2023","unstructured":"Alves da Costa F, Cardoso Borges F, Ramos A, Mayer A, Brito C, Ramos C, et al. Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice. Breast Cancer Res. 2023;25:78. https:\/\/doi.org\/10.1186\/s13058-023-01678-5.","journal-title":"Breast Cancer Res"},{"key":"1118_CR63","doi-asserted-by":"publisher","first-page":"1203684","DOI":"10.3389\/fonc.2023.1203684","volume":"13","author":"NH Al-Ziftawi","year":"2023","unstructured":"Al-Ziftawi NH, Elazzazy S, Alam MF, Shafie A, Anas Hamad A, Bbujassoum S, et al. The effectiveness and safety of palbociclib and ribociclib in stage IV HR+\/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study. Front Oncol. 2023;13:1203684. https:\/\/doi.org\/10.3389\/fonc.2023.1203684.","journal-title":"Front Oncol"},{"key":"1118_CR64","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3390\/curroncol28030209","volume":"28","author":"CP Amaro","year":"2021","unstructured":"Amaro CP, Batra A, Lupichuk S. First-line treatment with a cyclin-dependent kinase 4\/6 inhibitor plus an aromatase inhibitor for metastatic breast cancer in Alberta. Curr Oncol. 2021;28:2270\u201380. https:\/\/doi.org\/10.3390\/curroncol28030209.","journal-title":"Curr Oncol"},{"key":"1118_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10549-019-05134-x","volume":"174","author":"NML Battisti","year":"2019","unstructured":"Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, et al. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Res Treat. 2019;174:731\u201340. https:\/\/doi.org\/10.1007\/s10549-019-05134-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR66","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.26355\/eurrev_202306_32641","volume":"27","author":"E Bayram","year":"2023","unstructured":"Bayram E, Selvi O, K\u00f6\u015feci T, Mete B, Yasl\u0131kaya \u015e, Payda\u015f S. Comparison of different cyclin-dependent kinase inhibitors and KI-67 levels on survival and toxicity in breast cancer treatment. Eur Rev Med Pharmacol Sci. 2023;27:5230\u20139. https:\/\/doi.org\/10.26355\/eurrev_202306_32641.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1118_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12885-021-07790-z","volume":"21","author":"DC Beachler","year":"2021","unstructured":"Beachler DC, de Luise C, Jamal-Allial A, Yin R, Taylor DH, Suzuki A, et al. Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. BMC Cancer. 2021;21:97. https:\/\/doi.org\/10.1186\/s12885-021-07790-z.","journal-title":"BMC Cancer"},{"key":"1118_CR68","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10549-022-06823-w","volume":"197","author":"J Franks","year":"2023","unstructured":"Franks J, Caston NE, Elkhanany A, Gerke T, Azuero A, Rocque GB. Effect of prior treatments on post-CDK 4\/6 inhibitor survival in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2023;197:673\u201381. https:\/\/doi.org\/10.1007\/s10549-022-06823-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.clbc.2019.04.005","volume":"19","author":"A Brufsky","year":"2019","unstructured":"Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, et al. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR(+)\/HER2(\u2212) advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019;19:317-25.e4. https:\/\/doi.org\/10.1016\/j.clbc.2019.04.005.","journal-title":"Clin Breast Cancer"},{"key":"1118_CR70","doi-asserted-by":"publisher","first-page":"1237751","DOI":"10.3389\/fonc.2023.1237751","volume":"13","author":"A Brufsky","year":"2023","unstructured":"Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751. https:\/\/doi.org\/10.3389\/fonc.2023.1237751.","journal-title":"Front Oncol"},{"key":"1118_CR71","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/10781552231163121","volume":"29","author":"W Buller","year":"2023","unstructured":"Buller W, Pallan L, Chu T, Khoja L. CDK4\/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset. J Oncol Pharm Pract. 2023;29:1825\u201335. https:\/\/doi.org\/10.1177\/10781552231163121.","journal-title":"J Oncol Pharm Pract"},{"key":"1118_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.breast.2023.06.006","volume":"70","author":"E Caliskan Yildirim","year":"2023","unstructured":"Caliskan Yildirim E, Atag E, Coban E, Unal OU, Celebi A, Keser M, et al. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4\/6 inhibitor and endocrine therapy: a multicentric retrospective study. Breast. 2023;70:56\u201362. https:\/\/doi.org\/10.1016\/j.breast.2023.06.006.","journal-title":"Breast"},{"key":"1118_CR73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.breast.2022.02.005","volume":"62","author":"F Cardoso Borges","year":"2022","unstructured":"Cardoso Borges F, Alves da Costa F, Ramos A, Ramos C, Bernardo C, Brito C, et al. Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: results from a population-based cohort study. Breast. 2022;62:135\u201343. https:\/\/doi.org\/10.1016\/j.breast.2022.02.005.","journal-title":"Breast"},{"key":"1118_CR74","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.3390\/cancers14204981","volume":"14","author":"F Carlino","year":"2022","unstructured":"Carlino F, Diana A, Ventriglia A, Piccolo A, Mocerino C, Riccardi F, et al. HER2-low status does not affect survival outcomes of patients with metastatic breast cancer (mbc) undergoing first-line treatment with endocrine therapy plus palbociclib: results of a multicenter, retrospective cohort study. Cancers. 2022;14:4981. https:\/\/doi.org\/10.3390\/cancers14204981.","journal-title":"Cancers"},{"key":"1118_CR75","doi-asserted-by":"publisher","first-page":"8488","DOI":"10.3390\/ijms24108488","volume":"24","author":"M Cejuela","year":"2023","unstructured":"Cejuela M, Gil-Torralvo A, Castilla M, Dom\u00ednguez-Cejudo M, Falc\u00f3n A, Benavent M, et al. Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int J Mol Sci. 2023;24:8488. https:\/\/doi.org\/10.3390\/ijms24108488.","journal-title":"Int J Mol Sci"},{"key":"1118_CR76","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","volume":"188","author":"S Chawla","year":"2021","unstructured":"Chawla S, Hill A, Fearfield L, Johnston S, Parton M, Heelan K. Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience. Breast Cancer Res Treat. 2021;188:535\u201345. https:\/\/doi.org\/10.1007\/s10549-021-06169-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-022-06713-1","volume":"196","author":"GM Choong","year":"2022","unstructured":"Choong GM, Liddell S, Ferre RAL, O\u2019Sullivan CC, Ruddy KJ, Haddad TC, et al. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4\/6 inhibitors: a retrospective single-institution study. Breast Cancer Res Treat. 2022;196:229\u201337. https:\/\/doi.org\/10.1007\/s10549-022-06713-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR78","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-019-05181-4","volume":"175","author":"K Clifton","year":"2019","unstructured":"Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M. Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Res Treat. 2019;175:667\u201374. https:\/\/doi.org\/10.1007\/s10549-019-05181-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR79","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11523-023-00979-1","volume":"18","author":"A DeMichele","year":"2023","unstructured":"DeMichele A, Robert N, Chen C, Kim S, Zhang Z, Lu DR, et al. Real-world tumor response of palbociclib in combination with an aromatase inhibitor as first-line therapy in pre\/perimenopausal women with metastatic breast cancer. Target Oncol. 2023;18:543\u201358. https:\/\/doi.org\/10.1007\/s11523-023-00979-1.","journal-title":"Target Oncol"},{"key":"1118_CR80","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.breast.2021.10.010","volume":"60","author":"S El Badri","year":"2021","unstructured":"El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M, et al. Palbociclib in combination with aromatase inhibitors in patients \u2265 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: a real-world multicentre UK study. Breast. 2021;60:199\u2013205. https:\/\/doi.org\/10.1016\/j.breast.2021.10.010.","journal-title":"Breast"},{"key":"1118_CR81","doi-asserted-by":"publisher","first-page":"8994954","DOI":"10.1155\/2023\/8994954","volume":"2023","author":"K Elnaghi","year":"2023","unstructured":"Elnaghi K, Alghanmi HA, Elsamany SA, Almarzoki F, Elsafty M, Jaffal M. Hormonal-receptors-positive and HER2-negative patients with metastatic breast cancer treated with first-line palbociclib and hormonal therapy: impact of first-cycle neutropenia and dose reduction on therapeutic outcome. Breast. 2023;2023:8994954. https:\/\/doi.org\/10.1155\/2023\/8994954.","journal-title":"Breast"},{"key":"1118_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/ol.2021.13143","volume":"23","author":"G Emile","year":"2022","unstructured":"Emile G, Penager S, Levy C, Johnson A, Allouache D, Lequesne J, et al. Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncol Lett. 2022;23:25. https:\/\/doi.org\/10.3892\/ol.2021.13143.","journal-title":"Oncol Lett"},{"key":"1118_CR83","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s12282-023-01485-y","volume":"30","author":"M Futamura","year":"2023","unstructured":"Futamura M, Nakayama T, Yoshinami T, Oshiro C, Ishihara M, Morita M, et al. Detection of high-risk patients resistant to CDK4\/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast Cancer. 2023;30:943\u201351. https:\/\/doi.org\/10.1007\/s12282-023-01485-y.","journal-title":"Breast Cancer"},{"key":"1118_CR84","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3332\/ecancer.2022.1450","volume":"16","author":"S Ganguly","year":"2022","unstructured":"Ganguly S, Mukherjee N, Mandal S, Roy S, Agarwal S, Biswas B, et al. Efficacy of cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India. Ecancermedicalscience. 2022;16:1450. https:\/\/doi.org\/10.3332\/ecancer.2022.1450.","journal-title":"Ecancermedicalscience."},{"key":"1118_CR85","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/0284186X.2023.2194030","volume":"62","author":"R Garly","year":"2023","unstructured":"Garly R, Berg T, Jensen MB, Knoop A, Volmer L, Glavicic V, et al. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+\/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark. Acta Oncol. 2023;62:290\u20137. https:\/\/doi.org\/10.1080\/0284186X.2023.2194030.","journal-title":"Acta Oncol"},{"key":"1118_CR86","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cncr.34675","volume":"129","author":"RK Goyal","year":"2023","unstructured":"Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2\u2212 metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023;129:1051\u201363. https:\/\/doi.org\/10.1002\/cncr.34675.","journal-title":"Cancer"},{"key":"1118_CR87","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ijc.33959","volume":"150","author":"MJ Ha","year":"2022","unstructured":"Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, et al. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+\/HER2\u2212 metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: a large institutional study. Int J Cancer. 2022;150:2025\u201337. https:\/\/doi.org\/10.1002\/ijc.33959.","journal-title":"Int J Cancer"},{"key":"1118_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100691","volume":"35","author":"MQN Hackert","year":"2023","unstructured":"Hackert MQN, van Uden-Kraan CF, Agterof MJ, van der Velden AWG, Vriens BEPJ, Janssen JJB, et al. Real-world palbociclib effectiveness in patients with metastatic breast cancer: focus on neutropenia-related treatment modification strategies and clinical outcomes. Cancer Treat Res Commun. 2023;35: 100691. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100691.","journal-title":"Cancer Treat Res Commun."},{"key":"1118_CR89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-020-05750-y","volume":"183","author":"A Ham","year":"2020","unstructured":"Ham A, Kim MH, Kim GM, Kim JH, Kim JY, Park HS, et al. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183:107\u201316. https:\/\/doi.org\/10.1007\/s10549-020-05750-y.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR90","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/1759-7714.14715","volume":"14","author":"C Hao","year":"2023","unstructured":"Hao C, Bai X, Zhang J, Meng W, Tong Z. Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+\/HER2\u2212 advanced breast cancer. Thorac Cancer. 2023;14:68\u201372. https:\/\/doi.org\/10.1111\/1759-7714.14715.","journal-title":"Thorac Cancer."},{"key":"1118_CR91","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","volume":"60","author":"RK Ismail","year":"2021","unstructured":"Ismail RK, van Breeschoten J, Wouters M, van Dartel M, van der Flier S, Reyners AKL, et al. Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast. 2021;60:263\u201371. https:\/\/doi.org\/10.1016\/j.breast.2021.11.013.","journal-title":"Breast"},{"key":"1118_CR92","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/fon-2022-1287","volume":"19","author":"S Kahraman","year":"2023","unstructured":"Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, et al. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer. Future Oncol. 2023;19:727\u201336. https:\/\/doi.org\/10.2217\/fon-2022-1287.","journal-title":"Future Oncol"},{"key":"1118_CR93","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-022-06816-9","volume":"197","author":"M Kawai","year":"2023","unstructured":"Kawai M, Takada M, Nakayama T, Masuda N, Shiheido H, Cai Z, et al. Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database. Breast Cancer Res Treat. 2023;197:435\u201347. https:\/\/doi.org\/10.1007\/s10549-022-06816-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759150","volume":"11","author":"JY Kim","year":"2021","unstructured":"Kim JY, Oh JM, Park YH, Ahn JS, Im YH. Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer? Front Oncol. 2021;11: 759150. https:\/\/doi.org\/10.3389\/fonc.2021.759150.","journal-title":"Front Oncol"},{"key":"1118_CR95","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4143\/crt.2022.1543","volume":"55","author":"SG Kim","year":"2023","unstructured":"Kim SG, Kim MH, Park S, Kim GM, Kim JH, Kim JY, et al. Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. Cancer Res Treat. 2023;55:1198\u2013209. https:\/\/doi.org\/10.4143\/crt.2022.1543.","journal-title":"Cancer Res Treat"},{"key":"1118_CR96","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/oncolo\/oyac089","volume":"27","author":"ES Knudsen","year":"2022","unstructured":"Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O\u2019Connor T, et al. Real-world experience with CDK4\/6 inhibitors for metastatic HR+\/HER2\u2212 breast cancer at a single cancer center. Oncologist. 2022;27:646\u201354. https:\/\/doi.org\/10.1093\/oncolo\/oyac089.","journal-title":"Oncologist"},{"key":"1118_CR97","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-021-06215-6","volume":"188","author":"KB Kristensen","year":"2021","unstructured":"Kristensen KB, Thomsen IMN, Berg T, Kodahl AR, Jensen AB. Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2\u2212 metastatic breast cancer. Breast Cancer Res Treat. 2021;188:799\u2013809. https:\/\/doi.org\/10.1007\/s10549-021-06215-6.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10549-023-06993-1","volume":"201","author":"M Kruse","year":"2023","unstructured":"Kruse M, Smyth EN, Bowman L, Gautam S, Guimaraes CM, Nisbett AR, et al. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2\u2212 MBC in the real world. Breast Cancer Res Treat. 2023;201:105\u201315. https:\/\/doi.org\/10.1007\/s10549-023-06993-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR99","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/cancers15030690","volume":"15","author":"M Kubeczko","year":"2023","unstructured":"Kubeczko M, Gabry\u015b D, Gawkowska M, Polakiewicz-Gilowska A, Cortez AJ, Krzywon A, et al. Safety and feasibility of radiation therapy combined with CDK 4\/6 inhibitors in the management of advanced breast cancer. Cancers. 2023;15:690. https:\/\/doi.org\/10.3390\/cancers15030690.","journal-title":"Cancers"},{"key":"1118_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad304","author":"J-I Lai","year":"2023","unstructured":"Lai J-I, Kuo T-H, Huang K-J, Chai LMX, Lee M-H, Liu C-Y, et al. Clinical and genotypic insights into higher prevalence of palbociclib associated neutropenia in Asian patients. Oncologist. 2023. https:\/\/doi.org\/10.1093\/oncolo\/oyad304.","journal-title":"Oncologist"},{"key":"1118_CR101","doi-asserted-by":"publisher","first-page":"9803","DOI":"10.1007\/s00520-022-07400-z","volume":"30","author":"L Lavery","year":"2022","unstructured":"Lavery L, DiSogra K, Lea J, Trufan SJ, Symanowski JT, Roberts A, et al. Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer. Support Care Cancer. 2022;30:9803\u20139. https:\/\/doi.org\/10.1007\/s00520-022-07400-z.","journal-title":"Support Care Cancer"},{"key":"1118_CR102","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/curroncol29020089","volume":"29","author":"JW Law","year":"2022","unstructured":"Law JW, Mitra D, Kaplan HG, Alfred T, Brufsky AM, Emir B, et al. Real-world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first-line therapy in advanced\/metastatic breast cancer: analysis from the US syapse learning health network. Curr Oncol. 2022;29:1047\u201361. https:\/\/doi.org\/10.3390\/curroncol29020089.","journal-title":"Curr Oncol"},{"key":"1118_CR103","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4143\/crt.2020.451","volume":"53","author":"J Lee","year":"2021","unstructured":"Lee J, Park HS, Won HS, Yang JH, Lee HY, Woo IS, et al. Real-world clinical data of palbociclib in Asian metastatic breast cancer patients: experiences from eight institutions. Cancer Res Treat. 2021;53:409\u201323. https:\/\/doi.org\/10.4143\/crt.2020.451.","journal-title":"Cancer Res Treat"},{"key":"1118_CR104","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/cancers15102810","volume":"15","author":"Y Lee","year":"2023","unstructured":"Lee Y, Lee D, Seo I, Chae H, Sim SH, Lee KS, et al. Risk factors for palbociclib-induced early developing neutropenia in patients with hormone receptor-positive metastatic breast cancer. Cancers. 2023;15:2810. https:\/\/doi.org\/10.3390\/cancers15102810.","journal-title":"Cancers"},{"key":"1118_CR105","doi-asserted-by":"publisher","first-page":"175883592110228","DOI":"10.1177\/17588359211022890","volume":"13","author":"Y Li","year":"2021","unstructured":"Li Y, Li W, Gong C, Zheng Y, Ouyang Q, Xie N, et al. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+\/HER2\u2212 metastatic breast cancer. Ther Adv Med Oncol. 2021;13:17588359211022890. https:\/\/doi.org\/10.1177\/17588359211022890.","journal-title":"Ther Adv Med Oncol."},{"key":"1118_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35174","author":"X Liang","year":"2024","unstructured":"Liang X, Zhang L, Gui X, Di L, Li H, Song G. Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: a comparison of subsequent treatment patterns and HER2 expression analysis. Cancer. 2024. https:\/\/doi.org\/10.1002\/cncr.35174.","journal-title":"Cancer"},{"key":"1118_CR107","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.927187","volume":"26","author":"C Liu","year":"2020","unstructured":"Liu C, Li T, Tao Z, Cao J, Wang L, Zhang J, et al. Clinical outcomes of 130 patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with palbociclib plus endocrine therapy and subsequent therapy: a real-world single-center retrospective study in China. Med Sci Monit. 2020;26: e927187. https:\/\/doi.org\/10.12659\/MSM.927187.","journal-title":"Med Sci Monit"},{"key":"1118_CR108","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.breast.2020.11.005","volume":"54","author":"L Manso","year":"2020","unstructured":"Manso L, Hernando C, Gal\u00e1n M, Oliveira M, Cabrera MA, Bratos R, et al. Palbociclib combined with endocrine therapy in heavily pretreated HR(+)\/HER2(\u2212) advanced breast cancer patients: results from the compassionate use program in Spain (PALBOCOMP). Breast. 2020;54:286\u201392. https:\/\/doi.org\/10.1016\/j.breast.2020.11.005.","journal-title":"Breast"},{"key":"1118_CR109","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3390\/diagnostics13111938","volume":"13","author":"AI Miron","year":"2023","unstructured":"Miron AI, Anghel AV, Barnonschi AA, Mitre R, Liscu HD, G\u0103inariu E, et al. Real-World outcomes of CDK4\/6 inhibitors treatment in metastatic breast cancer in Romania. Diagnostics. 2023;13:1983. https:\/\/doi.org\/10.3390\/diagnostics13111938.","journal-title":"Diagnostics"},{"key":"1118_CR110","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1097\/CM9.0000000000002240","volume":"135","author":"H Mo","year":"2022","unstructured":"Mo H, Ma F, Li Q, Zhang P, Yuan P, Wang J, et al. Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. Chin Med J. 2022;135:1734\u201341. https:\/\/doi.org\/10.1097\/CM9.0000000000002240.","journal-title":"Chin Med J"},{"key":"1118_CR111","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.21873\/anticanres.16447","volume":"43","author":"M Morita","year":"2023","unstructured":"Morita M, Ooe A, Ishii W, Watanabe A, Matsui C, Okuyama Y, et al. Optimal treatment of hormone receptor-positive advanced breast cancer patients with palbociclib. Anticancer Res. 2023;43:2783\u20139. https:\/\/doi.org\/10.21873\/anticanres.16447.","journal-title":"Anticancer Res"},{"key":"1118_CR112","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2217\/fon-2023-0176","volume":"19","author":"SS Moser","year":"2023","unstructured":"Moser SS, Mazursky OF, Shalev H, Apter L, Chodick G, Siegelmann-Danieli N. Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations. Future Oncol. 2023;19:1473\u201383. https:\/\/doi.org\/10.2217\/fon-2023-0176.","journal-title":"Future Oncol"},{"key":"1118_CR113","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000527917","volume":"18","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller C, Kiver V, Solomayer EF, Wagenpfeil G, Neeb C, Blohmer JU, et al. CDK4\/6 Inhibitors in advanced HR+\/HER2\u2212 breast cancer: a multicenter real-world data analysis. Breast Care. 2023;18:31\u201341. https:\/\/doi.org\/10.1159\/000527917.","journal-title":"Breast Care."},{"key":"1118_CR114","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.clinthera.2022.11.004","volume":"44","author":"K Mycock","year":"2022","unstructured":"Mycock K, Hanson KA, Taylor-Stokes G, Milligan G, Atkinson C, Mitra D, et al. Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the ibrance real world insights study. Clin Ther. 2022;44:1588\u2013601. https:\/\/doi.org\/10.1016\/j.clinthera.2022.11.004.","journal-title":"Clin Ther"},{"key":"1118_CR115","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12282-023-01461-6","volume":"30","author":"K Nozawa","year":"2023","unstructured":"Nozawa K, Terada M, Onishi M, Ozaki Y, Takano T, Fakhouri W, et al. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2\u2212 metastatic breast cancer patients in Japan. Breast Cancer. 2023;30:657\u201365. https:\/\/doi.org\/10.1007\/s12282-023-01461-6.","journal-title":"Breast Cancer"},{"key":"1118_CR116","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41416-023-02352-5","volume":"129","author":"C Palmieri","year":"2023","unstructured":"Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, Macpherson IR, et al. A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK national health service as part of the novel Ibrance\u00ae patient program. Br J Cancer. 2023;129:852\u201360. https:\/\/doi.org\/10.1038\/s41416-023-02352-5.","journal-title":"Br J Cancer"},{"key":"1118_CR117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-022-06566-8","volume":"196","author":"SY Park","year":"2022","unstructured":"Park SY, Suh KJ, Lee DW, Ryu HS, Kim M, Kim SH, et al. Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy. Breast Cancer Res Treat. 2022;196:121\u20138. https:\/\/doi.org\/10.1007\/s10549-022-06566-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR118","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.1002\/jcp.27832","volume":"234","author":"L Pizzuti","year":"2019","unstructured":"Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, et al. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience. J Cell Physiol. 2019;234:7708\u201317. https:\/\/doi.org\/10.1002\/jcp.27832.","journal-title":"J Cell Physiol"},{"key":"1118_CR119","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.breast.2020.11.008","volume":"54","author":"B Porte","year":"2020","unstructured":"Porte B, Carton M, Lerebours F, Brain E, Loirat D, Haroun L, et al. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer. Breast. 2020;54:303\u201310. https:\/\/doi.org\/10.1016\/j.breast.2020.11.008.","journal-title":"Breast"},{"key":"1118_CR120","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/03007995.2022.2073122","volume":"38","author":"GL Price","year":"2022","unstructured":"Price GL, Sudharshan L, Ryan P, Rajkumar J, Sheffield KM, Smyth EN, et al. Real world incidence and management of adverse events in patients with HR+, HER2\u2013 metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. Curr Med Res Opin. 2022;38:1319\u201331. https:\/\/doi.org\/10.1080\/03007995.2022.2073122.","journal-title":"Curr Med Res Opin"},{"key":"1118_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100683","volume":"35","author":"MM Queiroz","year":"2023","unstructured":"Queiroz MM, Sacardo KP, Ribeiro MF, Gadotti LL, Saddi R, de Carvalho Oliveira LJ, et al. Real-world treatment outcomes in HR+ HER2\u2013 metastatic breast cancer patients treated with CDK4\/6 inhibitors: results from a reference center in Brazil. Cancer Treat Res Commun. 2023;35: 100683. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100683.","journal-title":"Cancer Treat Res Commun."},{"key":"1118_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253722","volume":"16","author":"S Rath","year":"2021","unstructured":"Rath S, Elamarthi P, Parab P, Gulia S, Nandhana R, Mokal S, et al. Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice. PLoS ONE. 2021;16: e0253722. https:\/\/doi.org\/10.1371\/journal.pone.0253722.","journal-title":"PLoS ONE"},{"key":"1118_CR123","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0858","author":"N Robert","year":"2024","unstructured":"Robert N, Chen C, Kim S, Zhang Z, Aguilar KM, Wang Y, et al. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer. Future Oncol. 2024. https:\/\/doi.org\/10.2217\/fon-2023-0858.","journal-title":"Future Oncol"},{"key":"1118_CR124","doi-asserted-by":"publisher","first-page":"1105587","DOI":"10.3389\/fonc.2022.1105587","volume":"12","author":"P Rottier","year":"2022","unstructured":"Rottier P, Emile G, Johnson A, Levy C, Allouache D, Hrab I, et al. Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4\/6 inhibitors. Front Oncol. 2022;12:1105587. https:\/\/doi.org\/10.3389\/fonc.2022.1105587.","journal-title":"Front Oncol"},{"key":"1118_CR125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/BCTT.S415432","volume":"15","author":"B Sharaf","year":"2023","unstructured":"Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, et al. Differences in treatment outcomes between patients with HER2-low versus HER2-zero, hormone receptor-positive advanced-stage breast cancer treated with ribociclib. Breast Cancer. 2023;15:541\u20138. https:\/\/doi.org\/10.2147\/BCTT.S415432.","journal-title":"Breast Cancer"},{"key":"1118_CR126","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1002\/cam4.4767","volume":"11","author":"L Shen","year":"2022","unstructured":"Shen L, Zhou J, Chen Y, Ding J, Wei H, Liu J, et al. Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: a multicenter ambispective real-world study. Cancer Med. 2022;11:4157\u201368. https:\/\/doi.org\/10.1002\/cam4.4767.","journal-title":"Cancer Med"},{"key":"1118_CR127","doi-asserted-by":"publisher","first-page":"117822342110651","DOI":"10.1177\/11782234211065148","volume":"16","author":"A Shikanai","year":"2022","unstructured":"Shikanai A, Horimoto Y, Ishizuka Y, Uomori T, Nakai K, Arakawa A, et al. Clinicopathological features related to the efficacy of CDK4\/6 inhibitor-based treatments in metastatic breast cancer. Breast Cancer. 2022;16:11782234211065148. https:\/\/doi.org\/10.1177\/11782234211065148.","journal-title":"Breast Cancer"},{"key":"1118_CR128","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1002\/cam4.4295","volume":"10","author":"J Sun","year":"2021","unstructured":"Sun J, Zhong X, Ma J, Sun W, Han HS, Soliman HH, et al. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 2021;10:7665\u201372. https:\/\/doi.org\/10.1002\/cam4.4295.","journal-title":"Cancer Med"},{"key":"1118_CR129","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.31557\/APJCP.2023.24.6.1955","volume":"24","author":"S Takada","year":"2023","unstructured":"Takada S, Maeda H, Umehara K, Kuwahara S, Yamamoto M, Tomioka N, et al. Clinical management of potential toxicity of abemaciclib and approaches to ensure treatment continuation. Asian Pac J Cancer Prev. 2023;24:1955\u201362. https:\/\/doi.org\/10.31557\/APJCP.2023.24.6.1955.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1118_CR130","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1248\/bpb.b23-00187","volume":"46","author":"S Takada","year":"2023","unstructured":"Takada S, Maeda H, Umehara K, Kuwahara S, Yamamoto M, Tomioka N, et al. Real-world predictors of severe neutropenia associated with palbociclib and endocrine therapy for metastatic breast cancer in Japanese patients. Biol Pharm Bull. 2023;46:1105\u201311. https:\/\/doi.org\/10.1248\/bpb.b23-00187.","journal-title":"Biol Pharm Bull"},{"key":"1118_CR131","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","volume":"176","author":"L Varella","year":"2019","unstructured":"Varella L, Eziokwu AS, Jia X, Kruse M, Moore HCF, Budd GT, et al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat. 2019;176:429\u201334. https:\/\/doi.org\/10.1007\/s10549-019-05176-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1118_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-11764-8","volume":"24","author":"W Wang","year":"2024","unstructured":"Wang W, Lei W, Fang Z, Jiang R, Wang X. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer. BMC Cancer. 2024;24:1. https:\/\/doi.org\/10.1186\/s12885-023-11764-8.","journal-title":"BMC Cancer"},{"key":"1118_CR133","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/ejh.13590","volume":"106","author":"MT West","year":"2021","unstructured":"West MT, Smith CE, Kaempf A, Kohs TCL, Amirsoltani R, Ribkoff J, et al. CDK 4\/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021;106:634\u201342. https:\/\/doi.org\/10.1111\/ejh.13590.","journal-title":"Eur J Haematol"},{"key":"1118_CR134","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/oncolo\/oyad035","volume":"28","author":"MT West","year":"2023","unstructured":"West MT, Goodyear SM, Hobbs EA, Kaempf A, Kartika T, Ribkoff J, et al. Real-world evaluation of disease progression after CDK 4\/6 inhibitor therapy in patients with hormone receptor-positive metastatic breast cancer. Oncologist. 2023;28:682\u201390. https:\/\/doi.org\/10.1093\/oncolo\/oyad035.","journal-title":"Oncologist"},{"key":"1118_CR135","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.clbc.2022.08.011","volume":"22","author":"V Wong","year":"2022","unstructured":"Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, et al. Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer. Clin Breast Cancer. 2022;22:792\u2013800. https:\/\/doi.org\/10.1016\/j.clbc.2022.08.011.","journal-title":"Clin Breast Cancer"},{"key":"1118_CR136","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.3390\/cancers15174360","volume":"15","author":"X Wu","year":"2023","unstructured":"Wu X, Jin N, Gao H, Yan M, Chen Q, Sun T, et al. Effectiveness and safety of palbociclib plus endocrine therapy in patients with advanced breast cancer: a multi-center study in China. Cancers. 2023;15:4360. https:\/\/doi.org\/10.3390\/cancers15174360.","journal-title":"Cancers"},{"key":"1118_CR137","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2018.7094","volume":"17","author":"J Xi","year":"2019","unstructured":"Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, et al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Canc Netw. 2019;17:141\u20137. https:\/\/doi.org\/10.6004\/jnccn.2018.7094.","journal-title":"J Natl Compr Canc Netw"},{"key":"1118_CR138","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12885-023-10568-0","volume":"23","author":"J Yang","year":"2023","unstructured":"Yang J, Zhao B, Ling X, Li D, Zhao J, Lv Y, et al. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China. BMC Cancer. 2023;23:103. https:\/\/doi.org\/10.1186\/s12885-023-10568-0.","journal-title":"BMC Cancer"},{"key":"1118_CR139","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.2217\/fon-2022-0464","volume":"18","author":"H Yilmaz","year":"2022","unstructured":"Yilmaz H, Nigdelioglu B, Aytac A, Turan M, Oktay E, Yersal O, et al. The prognostic importance of glucose-to-lymphocyte ratio and uric acid in metastatic breast cancer patients treated with Cdk 4\/6 inhibitors. Future Oncol. 2022;18:3043\u201353. https:\/\/doi.org\/10.2217\/fon-2022-0464.","journal-title":"Future Oncol"},{"key":"1118_CR140","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1097\/CAD.0000000000001210","volume":"33","author":"L Zhang","year":"2022","unstructured":"Zhang L, Song G, Shao B, Xu L, Xiao Y, Wang M, et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. Anticancer Drugs. 2022;33:e635\u201343. https:\/\/doi.org\/10.1097\/CAD.0000000000001210.","journal-title":"Anticancer Drugs"},{"key":"1118_CR141","doi-asserted-by":"publisher","first-page":"153303382312069","DOI":"10.1177\/15330338231206986","volume":"23","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Lan X, Huang J, Xie X, Chen L, Song L, et al. Combination of palbociclib and endocrine therapy in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer with or without brain metastases. Technol Cancer Res Treat. 2024;23:15330338231206986. https:\/\/doi.org\/10.1177\/15330338231206986.","journal-title":"Technol Cancer Res Treat"},{"key":"1118_CR142","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/0971-5851.190351","volume":"37","author":"R Pramanik","year":"2016","unstructured":"Pramanik R, Sahoo RK, Gogia A. Neutropenia due to palbociclib: a word of caution? Indian J Med Paediatr Oncol. 2016;37:206. https:\/\/doi.org\/10.4103\/0971-5851.190351.","journal-title":"Indian J Med Paediatr Oncol."},{"key":"1118_CR143","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26:e53-65. https:\/\/doi.org\/10.1002\/onco.13531.","journal-title":"Oncologist"},{"key":"1118_CR144","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","volume":"7","author":"S Gupta","year":"2021","unstructured":"Gupta S, Caza T, Herrmann SM, Sakhiya VC, Jhaveri KD. Clinicopathologic features of acute kidney injury associated eith CDK4\/6 Inhibitors. Kidney Int Rep. 2021;7:618\u201323. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.033.","journal-title":"Kidney Int Rep."},{"key":"1118_CR145","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000499534","volume":"14","author":"J Ettl","year":"2019","unstructured":"Ettl J. Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors. Breast Care. 2019;14:86\u201392. https:\/\/doi.org\/10.1159\/000499534.","journal-title":"Breast Care."},{"key":"1118_CR146","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326. https:\/\/doi.org\/10.1177\/1758835918793326.","journal-title":"Ther Adv Med Oncol."},{"key":"1118_CR147","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021;21:283\u201398. https:\/\/doi.org\/10.1080\/14737140.2021.1852934.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1118_CR148","doi-asserted-by":"publisher","first-page":"1269922","DOI":"10.3389\/fphar.2024.1269922","volume":"15","author":"D Pu","year":"2024","unstructured":"Pu D, Wu Y, Xu D, Shi G, Chen H, Feng D, et al. The adverse events of CDK4\/6 inhibitors for HR+\/ HER2\u2212 breast cancer: an umbrella review of meta-analyses of randomized controlled trials. Front Pharmacol. 2024;15:1269922. https:\/\/doi.org\/10.3389\/fphar.2024.1269922.","journal-title":"Front Pharmacol"},{"issue":"13","key":"1118_CR149","doi-asserted-by":"publisher","first-page":"81","DOI":"10.17161\/kjm.v13i1.13628","volume":"17","author":"R Atallah","year":"2020","unstructured":"Atallah R, Parker NA, Hamouche K, Truong QV, Dingwall M. Palbociclib-induced liver failure. Kans J Med. 2020;17(13):81\u20132.","journal-title":"Kans J Med."},{"key":"1118_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101098","volume":"6","author":"L Meunier","year":"2024","unstructured":"Meunier L, De Martin E, Delire B, Jacot W, Guiu S, Zahhaf A, et al. CDK4\/6 inhibitor-induced liver injury: clinical phenotypes and role of corticosteroid treatment. JHEP Rep. 2024;6: 101098. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101098.","journal-title":"JHEP Rep."},{"key":"1118_CR151","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.3390\/cancers15143590","volume":"15","author":"ZL Lim","year":"2023","unstructured":"Lim ZL, Ho PJ, Hartman M, Tan EY, Riza NKBM, Lim EH, et al. How Asian breast cancer patients experience unequal incidence of chemotherapy side effects: a look at ethnic disparities in febrile neutropenia rates. Cancers. 2023;15:3590. https:\/\/doi.org\/10.3390\/cancers15143590.","journal-title":"Cancers"},{"key":"1118_CR152","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1097\/JTO.0b013e31822722b6","volume":"6","author":"Y Hasegawa","year":"2011","unstructured":"Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. J Thorac Oncol. 2011;6:1881\u20138. https:\/\/doi.org\/10.1097\/JTO.0b013e31822722b6.","journal-title":"J Thorac Oncol"},{"key":"1118_CR153","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10549-018-5054-x","volume":"174","author":"KWC Lee","year":"2019","unstructured":"Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4\/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;174:271\u20138. https:\/\/doi.org\/10.1007\/s10549-018-5054-x.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01118-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T14:22:26Z","timestamp":1737814946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01118-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01118-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Chi Mei Medical Center and Taipei Medical University (grant number 112CM-TMU-08). The sponsoring organization was not involved in the study design, data analysis, or interpretation process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.-C.S., H.-W.L., and K.-W.T. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"H.-W.L. and K.-W.T. carried out study conception and design and wrote the manuscript; H.-C.S., H.-W.L., and K.-W.T. carried out data collection, assembly, analysis, and interpretation, and final proofreading and revision of manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}